Refractory Indolent Adult Non-Hodgkin Lymphoma
4 clinical trials · Condition
◉ Watch Refractory Indolent Adult Non-Hodgkin Lymphoma
| Record | Firm | Date |
|---|---|---|
| Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy (NCT04703686) | The Lymphoma Academic Research Organisation | 2021-03-30 |
| An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment (NCT04447716) | Thomas Jefferson University | 2020-10-16 |
| CAR-T Cells in Treating Patients With Relapsed or Refractory NHL (NCT04626739) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-04-01 |
| Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma (NCT03019640) | M.D. Anderson Cancer Center | 2017-10-10 |
Track Refractory Indolent Adult Non-Hodgkin Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.